Baseline Characteristics and Maintenance Therapy Choice on Symptom Control, Reliever Use, Exacerbation Risk in Moderate–Severe Asthma: A Clinical Modelling and Simulation Study
This study provided further insight into the effects of individual baseline characteristics on treatment response and highlighted significant differences in the performance of ICS/LABA combination therapy on symptom control, reliever use and exacerbation risk. These factors should be incorporated into clinical practice as the basis for tailored management of patients with moderate-severe asthma.
Authors
- Nicolás Roche (ORCID: https://orcid.org/0000-0002-3162-5033)
- Pierluigi Paggiaro (ORCID: https://orcid.org/0000-0002-1213-2989)
- Anurita Majumdar (ORCID: https://orcid.org/0000-0002-8047-9378)
- Maximilian Plank (ORCID: https://orcid.org/0000-0002-2111-1370)
- Manish Verma (ORCID: https://orcid.org/0000-0003-2618-4277)
- Janna K. Duong (ORCID: https://orcid.org/0000-0003-2347-7277)
- Sean Oosterholt (ORCID: https://orcid.org/0000-0002-4346-0088)
- Oscar E. Della Pasqua (ORCID: https://orcid.org/0000-0002-6211-1430)
- Gabriel García (ORCID: https://orcid.org/0000-0002-4268-4960)
Institutions
- University of Pisa (IT)
- Université Paris Cité (FR)
- Age UK (GB)
- Hôpital Cochin (FR)
- GlaxoSmithKline (Australia) (AU)
- GlaxoSmithKline (India) (IN)
- GlaxoSmithKline (Germany) (DE)
- University College London (GB)
- University of Newcastle Australia (AU)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1007/s12325-024-02962-2
- Citations
- 2
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.65
Funders
- GlaxoSmithKline